The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis

BMC Musculoskeletal Disorders

Michael Happich¹  Marie-Ange Paget⁴  James Gahn³  Karen Price²  Baoguang Han²  Ronald C Wielage³  Julie Myers³ 

[1] Lilly Deutschland GmbH, Bad Homburg, Germany;Eli Lilly and Company, Indianapolis, IN, USA;Medical Decision Modeling, Inc, 8909 Purdue Road, Suite 550, Indianapolis, IN, USA;Lilly France, Neuilly sur Seine, France

关键词: WOMAC;    Opioid;    NSAID;    Meta-analysis;    Osteoarthritis;    Duloxetine;   

Others  :  1128680
DOI  :  10.1186/1471-2474-15-76

 received in 2013-09-25, accepted in 2014-02-28,  发布年份 2014

【 摘 要 】

Background

This meta-analysis assessed the efficacy of duloxetine versus other oral treatments used after failure of acetaminophen for management of patients with osteoarthritis.

Methods

A systematic literature review of English language articles was performed in PUBMED, EMBASE, MedLine In-Process, Cochrane Library, and ClinicalTrials.gov between January 1985 and March 2013. Randomized controlled trials of duloxetine and all oral non-steroidal anti-inflammatory drugs and opioids were included if treatment was ≥12 weeks and the Western Ontario and McMaster Universities Index (WOMAC) total score was available. Studies were assessed for quality using the assessment tool from the National Institute for Health and Clinical Excellence guidelines for single technology appraisal submissions.

WOMAC baseline and change from baseline total scores were extracted and standardized. A frequentist meta-analysis, meta-regression, and indirect comparison were performed using the DerSimonian-Laird and Bucher methods. Bayesian analyses with and without adjustment for study-level covariates were performed using noninformative priors.

Results

Thirty-two publications reported 34 trials (2 publications each reported 2 trials) that met inclusion criteria. The analyses found all treatments except oxycodone (frequentist) and hydromorphone (frequentist and Bayesian) to be more effective than placebo. Indirect comparisons to duloxetine found no significant differences for most of the compounds. Some analyses showed evidence of a difference with duloxetine for etoricoxib (better), tramadol and oxycodone (worse), but without consistent results between analyses. Forest plots revealed positive trends in overall efficacy improvement with baseline scores. Adjusting for baseline, the probability duloxetine is superior to other treatments ranges between 15% to 100%.

Limitations of this study include the low number of studies included in the analyses, the inclusion of only English language publications, and possible ecological fallacy associated with patient level characteristics.

Conclusions

This analysis suggests no difference between duloxetine and other post-first line oral treatments for osteoarthritis (OA) in total WOMAC score after approximately 12 weeks of treatment. Significant results for 3 compounds (1 better and 2 worse) were not consistent across performed analyses.

【 授权许可】

   
2014 Myers et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 4.

【 参考文献 】

• [1]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008, 16:137-162.
• [2]Zhang W, Nuki G, Moskowitz R, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 2010, 18:476-499.
• [3]National Collaborating Centre for Chronic Conditions: Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians; 2008.
• [4]American Academy of Orthopaedic Surgeons (AAOS): American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the Treatment of Osteoarthritis of the Knee (Non-Arthroplasty). Rosemont: IL; 2008.
• [5]Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K-P, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
• [6]Bjordal JM, Klovning A, Ljunggren AE, Slørdal L: Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007, 11:125-138.
• [7]Bjordal JM, Ljunggren AE, Klovning A, Slørdal L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004, 329:1317.
• [8]Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P: Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009., (4) Art No.: CD003115. DOI:10.1002/14651858.CD003115.pub3
• [9]Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R: Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil 2010, 18:289-296.
• [10]Cepeda MS, Camargo F, Zea C, Valencia L: Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006., (3) Art No.: CD005522. DOI: 10.1002/14651858.CD005522.pub2.
• [11]Garner SE, Fidan DD, Frankish R, Maxwell L: Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005., (1) Art No.: CD005115. DOI: 10.1002/14651858.CD005115.
• [12]Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS: Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J Int Med Res 2005, 33:21-41.
• [13]Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, Etropolski M: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010, 27:381-399.
• [14]Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004, 63:901-907.
• [15]Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G: Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006., (1) Art No.: CD004257. DOI: 10.1002/14651858.CD004257.pub2.
• [16]Porzio F: Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. Rheumatol Int 1993, 13:19-24.
• [17]Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS: Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008, 12:1-278. iii
• [18]Avouac J, Gossec L, Dougados M: Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil 2007, 15:957-965.
• [19]Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ: A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Care Res 2004, 51:746-754.
• [20]Riedemann PJ, Bersinic S, Cuddy LJ, Torrance GW, Tugwell PX: A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol 2095, 1993:20.
• [21]Towheed TE, Hochberg MC: A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 1997, 24:349-357.
• [22]Furlan A, Sandoval J, Mailis-Gagnon A, Tunks E: Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006, 174:1589-1594.
• [23]Mayyas F, Fayers P, Kaasa S, Dale O: A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage 2010, 39:296-308.
• [24]Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM: Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010., (1) Art No.: CD006605. DOI: 10.1002/14651858.CD006605.pub2.
• [25]Papaleontiou M, Henderson CR Jr, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, Reid MC: Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2010, 58:1353-1369.
• [26]Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP: A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011, 11:33-41.
• [27]Chappell A, Ossanna M, Liu-Seifert H, Iyengar S, Skljarevski V, Li L, Bennett R, Collins H: Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009, 146:253-260.
• [28]Gahimer J, Wernicke J, Yalcin I, Ossanna M, Wulster-Radcliffe M, Viktrup L: A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007, 23:175-184.
• [29]Cymbalta prescribing information. Indianapolis, IN: Eli Lilly and Company; 2011.
• [30]Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, et al.: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010, 149:177-193.
• [31]Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
• [32]The Information Centre for Health and Social Care: Prescription cost analysis: England 2009. Leeds: NHS Information Centre for Health and Social Care; 2010.
• [33]National Institute for Health and Clinical Excellence: Single Technology Appraisal (STA). Specification for manufacturer/sponsor submission of evidence. London: NICE; 2009.
• [34]Dougados M, LeClaire P, Van der Heijde D, Bloch DA, Bellamy N, Altman RD: A report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthr Cartil 2000, 8:395-403.
• [35]Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H: Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 2010, 69:374-379.
• [36]Gana TJ, Pascual ML, Fleming RR, Schein JR, Janagap CC, Xiang J, Vorsanger GJ: Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006, 22:1391-1401.
• [37]Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to Meta-Analysis. 1st edition. West Sussex: Wiley; 2009.
• [38]Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
• [39]Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’Amico R, Bradburn M, Eastwood AJ: Indirect comparisons of competing interventions. Health Technol Assess 2005, 9:1-134.
• [40]Song F, Harvey I, Lilford R: Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008, 61:455-463.
• [41]Song F, Altman DG, Glenny A-M, Deeks JJ: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326:472.
• [42]Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive Meta-Analysis. Biostat: Englewood NJ; 2005.
• [43]Dias S, Welton NJ, Sutton AJ, Ades AE: NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2012.
• [44]Dias S, Sutton AJ, Welton NJ, Ades AE: NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta- regression, bias and bias-adjustment. 2012.
• [45]Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ: Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009, 28:1861-1881.
• [46]Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010, 29:932-944.
• [47]Lunn DJ, Thomas A, Best N, Spiegelhalter D: WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
• [48]Dickson D, Hosie G, English J: The Primary Care Rheumatology Society OA Knee Study Group: a double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. Clin Res 2001, 4:41-52.
• [49]Abou-Raya S, Abou-Raya A, Helmii M: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing 2012, 41:646-652.
• [50]Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010, 30:489-505.
• [51]Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T: Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010, 62:3635-3644.
• [52]Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999, 74:1095-1105.
• [53]Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O’Brien K, Tershakovec AM: Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007, 46:496-507.
• [54]Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, Quessy SN: Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape J Med 2008, 10:259.
• [55]Burch F, Fishman R, Messina N, Corser B, Radulescu F, Sarbu A, Craciun-Nicodin MM, Chiriac R, Beaulieu A, Rodrigues J: Others: A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage 2007, 34:328-338.
• [56]Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
• [57]DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, Fleming B: Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther 2011, 18:216-226.
• [58]Essex MN, Bhadra P, Sands GH: Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res 2012, 40:1357-1370.
• [59]Fishman RL, Kistler CJ, Ellerbusch MT, Aparicio RT, Swami SS, Shirley ME, Jain AK, Fortier L, Robertson S, Bouchard S: Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag 2007, 3:273.
• [60]Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol 2006, 25:42-53.
• [61]Fleischmann RM, Caldwell JR, Roth SH, Tesser JR, Olson W, Kamin M: Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res 2001, 62:113-128.
• [62]Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M: Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011, 27:1243-1253.
• [63]Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP: Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002, 51:530-537.
• [64]Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001, 29:467-479.
• [65]Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS: Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005, 21:517-526.
• [66]Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, Castro R, Sanchez M, Detora LM, Ng J: Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002, 18:49-58.
• [67]Markenson JA, Croft J, Zhang PG, Richards P: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005, 21:524.
• [68]Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS: A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthr Cartil 2007, 15:1348-1356.
• [69]Rauck R, Rapoport R, Thipphawong J: Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. Pain Pract 2013, 13:18-29.
• [70]Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, Maxwell T: A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clin Rheumatol 2011, 30:1433-1446.
• [71]Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M: Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum 2011, 40:285-297.
• [72]Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B: Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthr Cartil 2010, 18:629-639.
• [73]Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS: Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005, 27:64-77.
• [74]Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:161-168.
• [75]Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004, 63:1419-1426.
• [76]Vojtaššák J, Vojtaššák J, Jacobs A, Rynn L, Waechter S, Richarz U: A phase iiib, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of oros hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee. Pain Res Treat 2011, 2011:239501.
• [77]Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, Aversano ML, Reicin AS: Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:470-479.
• [78]Higgins J, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
• [79]Higgins JPT, Green S: (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 edition. Wiley Online Library; 2011. http://www.cochrane-handbook.org webcite
• [80]Spiegelhalter D, Best N, Carlin B, Van Der Linde A: Bayesian measures of model complexity and fit (with discussion). J R Stat Soc 2002, 64:583-616. Series B
• [81]Corrigan R, Derry S, Wiffen PJ, Moore RA: Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012., (5) CD009486. DOI: 10.1002/14651858.CD009486.pub2.
• [82]National Collaborating Centre for Chronic Conditions: Osteoarthritis: National Clinical Guideline for Care and Management in Adults. Appendix D. London: Royal College of Physicians; 2008.
• [83]Choy E, Marshall D, Gabriel ZL, Mitchell SA: Gylee E. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism: Dakin HA; 2011.
• [84]Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009, 9:6. BioMed Central Full Text
• [85]Trijau S, Avouac J, Escalas C, Gossec L, Dougados M: Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil 2010, 18:1012-1018.
• [86]Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D: The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012, 28:138-144.
• [87]Etropolski M, Kelly K, Okamoto A, Rauschkolb C: Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther 2011, 28:401-417.